Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ebola Viral Infections-Pipeline Review, H1 2015

Ebola Viral Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ebola Viral Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ebola Viral Infections-Pipeline Review, H1 2015', provides an overview of the Ebola Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Ebola Viral Infections Overview 9

Therapeutics Development 10

Pipeline Products for Ebola Viral Infections-Overview 10

Pipeline Products for Ebola Viral Infections-Comparative Analysis 11

Ebola Viral Infections-Therapeutics under Development by Companies 12

Ebola Viral Infections-Therapeutics under Investigation by Universities/Institutes 16

Ebola Viral Infections-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Ebola Viral Infections-Products under Development by Companies 21

Ebola Viral Infections-Products under Investigation by Universities/Institutes 25

Ebola Viral Infections-Companies Involved in Therapeutics Development 26

Abivax S.A. 26

AmVac AG 27

AnGes MG, Inc. 28

Canopus BioPharma Incorporated 29

Crucell N.V. 30

Etubics Corporation 31

FIT Biotech Oy 32

GeoVax Labs, Inc. 33

GlaxoSmithKline plc 34

Hemispherx Biopharma, Inc. 35

Humabs BioMed SA 36

Immune Response BioPharma, Inc. 37

Immunovaccine, Inc. 38

Inovio Pharmaceuticals, Inc. 39

Kymab Limited 40

Medicago Inc. 41

Merck & Co., Inc. 42

Microbiotix, Inc. 43

Navigen Pharmaceuticals, Inc. 44

Novavax, Inc. 45

Peregrine Pharmaceuticals, Inc. 46

SignPath Pharma Inc 47

Sihuan Pharmaceutical Holdings Group Ltd. 48

SKAU Vaccines ApS 49

Tamir Biotechnology, Inc. 50

Tekmira Pharmaceuticals Corp. 51

Toyama Chemical Co., Ltd. 52

United Therapeutics Corporation 53

Vaxart, Inc. 54

XBiotech USA, Inc. 55

Ebola Viral Infections-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Combination Products 57

Assessment by Target 58

Assessment by Mechanism of Action 60

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

ABX-544-Drug Profile 66

Ad5-EBOV vaccine-Drug Profile 67

AMV-711-Drug Profile 68

ANSX-109-Drug Profile 69

ANSX-142-Drug Profile 70

Antibody for Ebola Viral Infection-Drug Profile 71

bavituximab-Drug Profile 72

CB-007-Drug Profile 77

CB-008-Drug Profile 78

DLANA-14-Drug Profile 79

DPX-Ebola-Drug Profile 80

ebola + marburg vaccine-Drug Profile 81

ebola + rabies vaccine-Drug Profile 82

ebola [strain sudan] vaccine-Drug Profile 83

ebola [strain zaire] vaccine-Drug Profile 84

ebola [strain zaire] vaccine-Drug Profile 85

ebola [zaire] vaccine-Drug Profile 86

ebola [zaire] vaccine-Drug Profile 87

ebola vaccine-Drug Profile 88

ebola vaccine-Drug Profile 91

ebola vaccine-Drug Profile 92

ebola vaccine-Drug Profile 94

ebola vaccine-Drug Profile 95

ebola vaccine-Drug Profile 96

ebola vaccine-Drug Profile 97

ebola vaccine-Drug Profile 98

ebola vaccine-Drug Profile 100

ebola vaccine-Drug Profile 101

ebola virus like particle vaccine-Drug Profile 102

ebola virus like particle vaccine-Drug Profile 103

ET-007-Drug Profile 104

favipiravir-Drug Profile 105

FBH-004-Drug Profile 107

FDX-000-Drug Profile 108

GBV-006-Drug Profile 109

Gene Therapy for Ebola Virus Infections-Drug Profile 110

GOVXE-301-Drug Profile 111

GOVXE-302-Drug Profile 112

GreEMTri-Drug Profile 113

imatinib mesylate-Drug Profile 114

INO-4212-Drug Profile 115

interferon alfa-n3-Drug Profile 116

IRE-101-Drug Profile 117

JK-05-Drug Profile 118

KV-7005-Drug Profile 119

Liposomal Curcumin-Drug Profile 120

MIL-77-Drug Profile 122

MMCatLMC-Drug Profile 123

Monoclonal Antibodies for Ebola Viral Infections-Drug Profile 124

Monoclonal Antibodies for Viral Infections-Drug Profile 125

Monoclonal Antibody for Ebola Viral Infections-Drug Profile 127

Monoclonal Antibody for Ebola Virus Infections-Drug Profile 128

NCK-8-Drug Profile 129

NoBola-Drug Profile 130

OS-2966-Drug Profile 131

rintatolimod-Drug Profile 132

Small Molecules for Ebola Virus Infection-Drug Profile 134

Small Molecules for Ebola Virus Infections-Drug Profile 135

Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection-Drug Profile 136

Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections-Drug Profile 137

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus-Drug Profile 138

Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections-Drug Profile 139

Small Molecules to Target Estrogen Receptor for Ebola Virus Infection-Drug Profile 140

Synthetic Peptides for Ebola Virus-Drug Profile 141

thiocarbazate-Drug Profile 142

TKM-100802-Drug Profile 143

TKM-Ebola-Guinea-Drug Profile 146

TMR-004-Drug Profile 147

UV-4B-Drug Profile 148

V-920-Drug Profile 149

ZMAb-Drug Profile 152

ZMapp-Drug Profile 154

Ebola Viral Infections-Recent Pipeline Updates 156

Ebola Viral Infections-Dormant Projects 186

Ebola Viral Infections-Discontinued Products 188

Ebola Viral Infections-Product Development Milestones 189

Featured News & Press Releases 189

Appendix 196

Methodology 196

Coverage 196

Secondary Research 196

Primary Research 196

Expert Panel Validation 196

Contact Us 196

Disclaimer 197

List of Tables

Number of Products under Development for Ebola Viral Infections, H1 2015 15

Number of Products under Development for Ebola Viral Infections-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Development by Companies, H1 2015 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Comparative Analysis by Unknown Stage Development, H1 2015 25

Products under Development by Companies, H1 2015 26

Products under Development by Companies, H1 2015 (Contd..1) 27

Products under Development by Companies, H1 2015 (Contd..2) 28

Products under Development by Companies, H1 2015 (Contd..3) 29

Products under Investigation by Universities/Institutes, H1 2015 30

Ebola Viral Infections-Pipeline by Abivax S.A., H1 2015 31

Ebola Viral Infections-Pipeline by AmVac AG, H1 2015 32

Ebola Viral Infections-Pipeline by AnGes MG, Inc., H1 2015 33

Ebola Viral Infections-Pipeline by Canopus BioPharma Incorporated, H1 2015 34

Ebola Viral Infections-Pipeline by Crucell N.V., H1 2015 35

Ebola Viral Infections-Pipeline by Etubics Corporation, H1 2015 36

Ebola Viral Infections-Pipeline by FIT Biotech Oy, H1 2015 37

Ebola Viral Infections-Pipeline by GeoVax Labs, Inc., H1 2015 38

Ebola Viral Infections-Pipeline by GlaxoSmithKline plc, H1 2015 39

Ebola Viral Infections-Pipeline by Hemispherx Biopharma, Inc., H1 2015 40

Ebola Viral Infections-Pipeline by Humabs BioMed SA, H1 2015 41

Ebola Viral Infections-Pipeline by Immune Response BioPharma, Inc., H1 2015 42

Ebola Viral Infections-Pipeline by Immunovaccine, Inc., H1 2015 43

Ebola Viral Infections-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 44

Ebola Viral Infections-Pipeline by Kymab Limited, H1 2015 45

Ebola Viral Infections-Pipeline by Medicago Inc., H1 2015 46

Ebola Viral Infections-Pipeline by Merck & Co., Inc., H1 2015 47

Ebola Viral Infections-Pipeline by Microbiotix, Inc., H1 2015 48

Ebola Viral Infections-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 49

Ebola Viral Infections-Pipeline by Novavax, Inc., H1 2015 50

Ebola Viral Infections-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 51

Ebola Viral Infections-Pipeline by SignPath Pharma Inc, H1 2015 52

Ebola Viral Infections-Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2015 53

Ebola Viral Infections-Pipeline by SKAU Vaccines ApS, H1 2015 54

Ebola Viral Infections-Pipeline by Tamir Biotechnology, Inc., H1 2015 55

Ebola Viral Infections-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 56

Ebola Viral Infections-Pipeline by Toyama Chemical Co., Ltd., H1 2015 57

Ebola Viral Infections-Pipeline by United Therapeutics Corporation, H1 2015 58

Ebola Viral Infections-Pipeline by Vaxart, Inc., H1 2015 59

Ebola Viral Infections-Pipeline by XBiotech USA, Inc., H1 2015 60

Assessment by Monotherapy Products, H1 2015 61

Assessment by Combination Products, H1 2015 62

Number of Products by Stage and Target, H1 2015 64

Number of Products by Stage and Mechanism of Action, H1 2015 66

Number of Products by Stage and Route of Administration, H1 2015 68

Number of Products by Stage and Molecule Type, H1 2015 70

Ebola Viral Infections Therapeutics-Recent Pipeline Updates, H1 2015 161

Ebola Viral Infections-Dormant Projects, H1 2015 191

Ebola Viral Infections-Dormant Projects (Contd..1), H1 2015 192

Ebola Viral Infections-Discontinued Products, H1 2015 193

List of Figures

Number of Products under Development for Ebola Viral Infections, H1 2015 15

Number of Products under Development for Ebola Viral Infections-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 61

Assessment by Combination Products, H1 2015 62

Number of Products by Top 10 Targets, H1 2015 63

Number of Products by Stage and Top 10 Targets, H1 2015 64

Number of Products by Top 10 Mechanism of Actions, H1 2015 65

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 66

Number of Products by Top 10 Routes of Administration, H1 2015 67

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 68

Number of Products by Top 10 Molecule Types, H1 2015 69

Number of Products by Stage and Top 10 Molecule Types, H1 2015 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abivax S.A.

AmVac AG

AnGes MG, Inc.

Canopus BioPharma Incorporated

Crucell N.V.

Etubics Corporation

FIT Biotech Oy

GeoVax Labs, Inc.

GlaxoSmithKline plc

Hemispherx Biopharma, Inc.

Humabs BioMed SA

Immune Response BioPharma, Inc.

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

Kymab Limited

Medicago Inc.

Merck & Co., Inc.

Microbiotix, Inc.

Navigen Pharmaceuticals, Inc.

Novavax, Inc.

Peregrine Pharmaceuticals, Inc.

SignPath Pharma Inc

Sihuan Pharmaceutical Holdings Group Ltd.

SKAU Vaccines ApS

Tamir Biotechnology, Inc.

Tekmira Pharmaceuticals Corp.

Toyama Chemical Co., Ltd.

United Therapeutics Corporation

Vaxart, Inc.

XBiotech USA, Inc.

Ebola Viral Infections Therapeutic Products under Development, Key Players in Ebola Viral Infections Therapeutics, Ebola Viral Infections Pipeline Overview, Ebola Viral Infections Pipeline, Ebola Viral Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com